Organoid-based drug discovery platform (ADIO)

ORGANOIDSCIENCES, Ltd. is a South Korea’s first biotech to develop first-in-class regenerative medicine for incurable diseases and a new drug development platform that can meet various unmet needs.

As we all know, organoids are a promising strategy in the field of drug discovery with high level reflecting the patient population heterogeneity and antigen expression. We have developed various organoid-based drug discovery platform such as anticancer drugs, antiviral drugs and antifibrotic agents evaluation.
In particular, we are specialized to evaluate the efficacy of patient-specific immune checkpoint inhibitors by using our own ADIO (Autologous organoids-based Discovery for Immuno-Oncology drug) platform that co-cultures tumor organoids with patient-derived immune cells.

Please see the attachment for further information.
We would also like to present more details of our innovative platforms for the drug development and discuss any possible collaborations.